Literature DB >> 30097761

Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Anita K Chisholm1,2, Vicki A Anderson3,4, Natalie A Pride5, Stephanie Malarbi3,4, Kathryn N North3,4, Jonathan M Payne6,7.   

Abstract

In light of the proliferation of recent research into social function in neurofibromatosis type 1 (NF1), a systematic review and meta-analysis is required to synthesise data and place findings within the context of a theoretical framework. This paper reviews findings from research into social function and autism spectrum disorder (ASD) in children and adults with NF1 and integrates these findings with the Socio-Cognitive Integration Abilities Model (SOCIAL). It also critically appraises links between social outcomes, internal and external factors moderating social functioning, cognitive domains implicated in social functioning, and underlying neural pathology in NF1. A systematic literature search conducted in MedLine (Ovid), PsycINFO (Ovid), Embase (Ovid), and PubMed electronic databases yielded 35 papers that met inclusion criteria for the systematic review. Out of these papers, 22 papers provided sufficient data for meta-analysis. Findings from this review and meta-analysis provide evidence that children and adults with NF1 exhibit significantly higher prevalence and severity of social dysfunction and ASD symptomatology. To date, very few studies have examined social cognition in NF1 but results indicate the presence of both perceptual and higher-level impairments in this population. The results of this review also provide support for age, gender, and comorbid ADHD as moderating factors for social outcomes in NF1. Suggestions for future research are offered to further our understanding of the social phenotype in NF1 and to facilitate the development of targeted interventions.

Entities:  

Keywords:  Autism spectrum disorder; Neurofibromatosis type 1; Social cognition; Social function; Social perception

Mesh:

Year:  2018        PMID: 30097761     DOI: 10.1007/s11065-018-9380-x

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  112 in total

Review 1.  The neurobiology of social cognition.

Authors:  R Adolphs
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

2.  IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP).

Authors:  T Charman; A Pickles; E Simonoff; S Chandler; T Loucas; G Baird
Journal:  Psychol Med       Date:  2011-03       Impact factor: 7.723

Review 3.  Disentangling the heterogeneity of autism spectrum disorder through genetic findings.

Authors:  Shafali S Jeste; Daniel H Geschwind
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

4.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

5.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

Review 6.  Attention deficit disorder: a review of the past 10 years.

Authors:  D P Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-08       Impact factor: 8.829

7.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

Authors:  Shelley L Hyman; E Arthur Shores; Kathryn N North
Journal:  Dev Med Child Neurol       Date:  2006-12       Impact factor: 5.449

8.  Social impairments in chromosome 22q11.2 deletion syndrome (22q11.2DS): autism spectrum disorder or a different endophenotype?

Authors:  Kathleen Angkustsiri; Beth Goodlin-Jones; Lesley Deprey; Khyati Brahmbhatt; Susan Harris; Tony J Simon
Journal:  J Autism Dev Disord       Date:  2014-04

9.  Children and adolescents with neurofibromatosis 1: a behavioral phenotype.

Authors:  C V Dilts; J C Carey; J C Kircher; R O Hoffman; D Creel; K Ward; E Clark; C O Leonard
Journal:  J Dev Behav Pediatr       Date:  1996-08       Impact factor: 2.225

Review 10.  Sex differences in autism spectrum disorders.

Authors:  Donna M Werling; Daniel H Geschwind
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

View more
  17 in total

1.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

2.  Discriminating between neurofibromatosis-1 and typically developing children by means of multimodal MRI and multivariate analyses.

Authors:  Federico Nemmi; Fabien Cignetti; Christine Assaiante; Stephanie Maziero; Fredrique Audic; Patrice Péran; Yves Chaix
Journal:  Hum Brain Mapp       Date:  2019-05-11       Impact factor: 5.038

3.  Enriched expression of NF1 in inhibitory neurons in both mouse and human brain.

Authors:  Hyun-Hee Ryu; Minkyung Kang; Jinsil Park; Sung-Hye Park; Yong-Seok Lee
Journal:  Mol Brain       Date:  2019-06-24       Impact factor: 4.041

4.  Reduced higher dimensional temporal dynamism in neurofibromatosis type 1.

Authors:  Eva Mennigen; Peter Schuette; Ariana Vajdi; Laura Pacheco; Tena Rosser; Carrie E Bearden
Journal:  Neuroimage Clin       Date:  2019-01-29       Impact factor: 4.881

5.  Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.

Authors:  Kristina M Haebich; Natalie A Pride; Karin S Walsh; Anita Chisholm; Melissa Rouel; Alice Maier; Vicki Anderson; Belinda Barton; Tim Silk; Mayuresh Korgaonkar; Marc Seal; Francesca Lami; Jennifer Lorenzo; Katrina Williams; Gabriel Dabscheck; Caroline D Rae; Michael Kean; Kathryn N North; Jonathan M Payne
Journal:  BMJ Open       Date:  2019-09-26       Impact factor: 2.692

6.  Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review.

Authors:  Beatriz Barreto-Duarte; Fabiana H Andrade-Gomes; María B Arriaga; Mariana Araújo-Pereira; Juan Manuel Cubillos-Angulo; Bruno B Andrade
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

7.  Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.

Authors:  Jennifer A Janusz; Bonita P Klein-Tasman; Jonathan M Payne; Pamela L Wolters; Heather L Thompson; Staci Martin; Peter de Blank; Nicole Ullrich; Allison Del Castillo; Maureen Hussey; Kristina K Hardy; Kristina Haebich; Tena Rosser; Mary Anne Toledo-Tamula; Karin S Walsh
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

8.  Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.

Authors:  J L Lukkes; H P Drozd; S D Fitz; A I Molosh; D W Clapp; A Shekhar
Journal:  J Neurodev Disord       Date:  2020-01-15       Impact factor: 4.025

9.  Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.

Authors:  Peter de Blank; Nan Li; Michael J Fisher; Nicole J Ullrich; Smita Bhatia; Yutaka Yasui; Charles A Sklar; Wendy Leisenring; Rebecca Howell; Kevin Oeffinger; Kristina Hardy; M Fatih Okcu; Todd M Gibson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Genet Med       Date:  2020-06-23       Impact factor: 8.864

10.  A novel RAB39B mutation and concurrent de novo NF1 mutation in a boy with neurofibromatosis type 1, intellectual disability, and autism: a case report.

Authors:  Claudia Santoro; Teresa Giugliano; Pia Bernardo; Federica Palladino; Annalaura Torella; Francesca Del Vecchio Blanco; Maria Elena Onore; Marco Carotenuto; Vincenzo Nigro; Giulio Piluso
Journal:  BMC Neurol       Date:  2020-09-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.